OBJECTIVES: The purpose of this study was to determine serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. DESIGN AND METHODS: Serum prolidase activity was measured spectrophotometrically in hypertensive patients with (Group II, n=30) and without left ventricular hypertrophy (Group III, n=30) and in control group (Group I, n=30). RESULTS: Prolidase activity was significantly lower in Group I than in Groups II and III (44.64+/-6.42 U/L vs. 54.14+/-6.30 U/L and 54.25+/-7.14 U/L, respectively; ANOVA, p<0.001). We revealed significant correlation between prolidase activity and presence and duration of hypertension (both of p<0.05) but not left ventricular mass index. Multivariate analysis shown that prolidase activity was significantly associated with age (beta=0.481, p<0.001) and duration of hypertension (beta=0.396, p<0.001). CONCLUSIONS: Our data show that serum prolidase activity is associated with the presence hypertension independent of left ventricular hypertrophy.
OBJECTIVES: The purpose of this study was to determine serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. DESIGN AND METHODS: Serum prolidase activity was measured spectrophotometrically in hypertensivepatients with (Group II, n=30) and without left ventricular hypertrophy (Group III, n=30) and in control group (Group I, n=30). RESULTS:Prolidase activity was significantly lower in Group I than in Groups II and III (44.64+/-6.42 U/L vs. 54.14+/-6.30 U/L and 54.25+/-7.14 U/L, respectively; ANOVA, p<0.001). We revealed significant correlation between prolidase activity and presence and duration of hypertension (both of p<0.05) but not left ventricular mass index. Multivariate analysis shown that prolidase activity was significantly associated with age (beta=0.481, p<0.001) and duration of hypertension (beta=0.396, p<0.001). CONCLUSIONS: Our data show that serum prolidase activity is associated with the presence hypertension independent of left ventricular hypertrophy.
Authors: Ibrahim Türkbeyler; Tuncer Demir; Yavuz Pehlivan; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Nurten Aksoy; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat Journal: Inflammation Date: 2012-10 Impact factor: 4.092
Authors: Refah Sayın; Mehmet Aslan; Mehmet Emin Kucukoglu; Arda Luleci; Murat Atmaca; Ramazan Esen; Halit Demir Journal: Endocrine Date: 2013-12-18 Impact factor: 3.633